Biotechnology company Tenaya Therapeutics Inc (NASDAQ:TNYA) reported on Monday the addition of June Lee, MD, to its board of directors.
The company added that JJ Kang, PhD will resign from board after five years of service to focus on her current role as CEO of Appia Bio and Venture Partner at The Column Group. Dr Kang has served as the company's board member 2016 as well as interim president for two years.
More recently, Dr Lee was the founder and CEO of Esker Therapeutics as well as executive vice president, chief development officer and chief operating officer of MyoKardia.
Previously, Dr Lee was the therapeutic area head for early clinical development in cardiovascular, metabolism, respiratory and infectious diseases at Genentech.
Currently, Dr Lee is a member of the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, board of director for Eledon Pharmaceuticals Inc and GenEdit, as well as the Scientific Advisory Board for Foresite Labs, respectively.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy